{
    "Clinical Trial ID": "NCT02162667",
    "Intervention": [
        "INTERVENTION 1: ",
        "  CT-P6",
        "  Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.",
        "INTERVENTION 2: ",
        "  Herceptin",
        "  Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patient who has histologically confirmed and newly diagnosed breast cancer",
        "  Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition",
        "  Patient who has HER2-positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry).",
        "Exclusion Criteria:",
        "  Patient who has bilateral breast cancer",
        "  Patient who has received prior treatment for breast cancer, including chemotherapy, biologic therapy, hormone therapy, immunotherapy, radiation or surgery, including any prior therapy with anthracyclines."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)",
        "  Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.",
        "  The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.",
        "  Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)",
        "Results 1: ",
        "  Arm/Group Title: CT-P6",
        "  Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.",
        "  Overall Number of Participants Analyzed: 248",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of responders  46.77        (40.43 to 53.19)",
        "Results 2: ",
        "  Arm/Group Title: Herceptin",
        "  Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.",
        "  Overall Number of Participants Analyzed: 256",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of responders  50.39        (44.10 to 56.68)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 22/271 (8.12%)",
        "  Anemia1/271 (0.37%)",
        "  Febrile neutropenia6/271 (2.21%)",
        "  Leukocytosis0/271 (0.00%)",
        "  Neutropenia2/271 (0.74%)",
        "  Acute myocardial infarction0/271 (0.00%)",
        "  Adams-Stokes syndrome1/271 (0.37%)",
        "  Angina pectoris0/271 (0.00%)",
        "  Congestive cardiomyopathy0/271 (0.00%)",
        "  Myocardial infarction0/271 (0.00%)",
        "  Dacryostenosis acquired0/271 (0.00%)",
        "Adverse Events 2:",
        "  Total: 36/278 (12.95%)",
        "  Anemia3/278 (1.08%)",
        "  Febrile neutropenia3/278 (1.08%)",
        "  Leukocytosis1/278 (0.36%)",
        "  Neutropenia3/278 (1.08%)",
        "  Acute myocardial infarction1/278 (0.36%)",
        "  Adams-Stokes syndrome0/278 (0.00%)",
        "  Angina pectoris1/278 (0.36%)",
        "  Congestive cardiomyopathy1/278 (0.36%)",
        "  Myocardial infarction1/278 (0.36%)",
        "  Dacryostenosis acquired1/278 (0.36%)"
    ]
}